DNA vs RXRX
DNA: Ginkgo Bioworks engineers biology at scale through lab automation, AI-driven R&D services, and biosecurity infrastructure to help customers develop new therapeutics, vaccines, industrial chemicals, and biological threat detection. RXRX: Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug discovery and development process.
Side-by-side fundamentals
| Metric | DNA | RXRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.83 | $2.98 | |
| Market cap as of 2026-07-23 | $511M | $1.6B | |
| Net margin as of 2026-07-23 | -215.4% | -842.9% | DNA higher |
| Gross margin as of 2026-07-23 | +73.1% | +7.2% | DNA higher |
| Operating margin as of 2026-07-23 | -220.9% | -881.3% | DNA higher |
| ROE as of 2026-07-23 | -57.3% | -54.3% | RXRX higher |
| ROA as of 2026-07-23 | -26.6% | -40.6% | DNA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.02 | DNA lower |
| Revenue growth (YoY) as of 2026-07-23 | -40.5% | +11.1% | RXRX higher |
| Revenue CAGR (3y) SEC XBRL | -29.1% | +23.3% | RXRX higher |
| Beta as of 2026-07-23 | 1.76 | 1.08 | |
| 1-year return as of 2026-07-22 close | -30.3% | -54.4% | DNA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.